Feasibility and Tolerance of Nivolumab Neoadjuvant Immunotherapy in High Risk HPV Driven Oropharynx Cancer

Summary

The aim of this research is to study the feasibility of neoadjuvant treatment before chemoradiation in "high risk" HPV-driven Oropharynx cancer

Timeline

Start

2019-07-25

Primary completion

2022-04-01

Completion

2024-11-20

Outcome

Missed primary endpoint

paper The primary end point was not met: four of 41 patients in EA received <200 mg/m2 cisplatin. PMID 41570275 ↗

Publications

• Mirghani H, Auperin A, Even C, Larive A, Fayette J, Geoffrois L, Clatot F, Calderon B, Tao Y, Nguyen F, Fabiano E, Kreps S, Gaultier AL, Bidault F, Puech J, Morin B, Picavet L, Tartour E, Ben Hariz A, Chevrot M, Monard L, Veyer D, Badoual C, Pere H, Blanchard P. Induction Nivolumab Before Chemoradiation in High-Risk Human Papillomavirus-Driven Oropharynx Cancers: IMMUNEBOOST-HPV, a Multicenter Randomized Phase II Trial. J Clin Oncol. 2026 Mar 20;44(9):787-800. doi: 10.1200/JCO-25-00835. Epub 2026 Jan 22.

Drugs

Indications